3-Methyladenine (3-MA)

For research use only. Not for use in humans.

Catalog No.S2767 Synonyms: NSC 66389

395 publications

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.

Size Price Stock Quantity  
USD 70 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's 3-Methyladenine (3-MA) has been cited by 395 publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NXHLTHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXizcW0> NHjGWFczcA>? NFvUeZhFVVOR MlHUdoVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? NYjOcY85OjV5MU[1OlE>
A549  Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXBN41O M1XNeFJp NFvydpNFVVOR MYDy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E NUT4S|ZkOjV5MU[1OlE>
95D M4LqfWFxd3C2b4Ppd{BCe3OjeR?= MX[1cW0> MofuNog> MX\EUXNQ NUjTPY1xcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo NVW2TY5qOjV5MU[1OlE>
A549  M1HtcWFxd3C2b4Ppd{BCe3OjeR?= MY[1cW0> NXjXOm5vOmh? NHrXXVhFVVOR M13aOYlvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= NEDiOFEzPTdzNkW2NS=>
NBL-W-S  M{CwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fvfVFuVQ>? NX6wVZdkPmh? NVXWblhC\W6qYX7j[ZMhT0GQVD22NUB1d3irY3n0fS=> NIS5S3czPTN{M{KyNi=>
NBL-W-S  NXHsdJI4SXCxcITvd4l{KEG|c3H5 Mof1NY1O Mn2wOog> MoPwbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgS2FPXC14MR?= NYDC[VZ1OjV|MkOyNlI>
A2780cp  NFfaUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLrNY1O NXPiTFRCOWh? Mn;qbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NWr3RYtUOjV|MkK2PVQ>
A549  MYrGeY5kfGmxbjDBd5NigQ>? NHPmV5M2dU1? MVyybC=> M{f4UJN2eHC{ZYPz[ZMhW1CFIHnu[JVk\WRiYXPjeY12dGG2aX;uJI9nKEyFMz3JTS=> MlvwNlUzQDV4Mki=
H157 M3u3SGZ2dmO2aX;uJGF{e2G7 NF7aWXI2dU1? NID0UGszcA>? NX;EXWZie3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MmeyNlUzQDV4Mki=
MDR MUXBdI9xfG:|aYOgRZN{[Xl? MWexNI1O NHvp[HU3cA>? M{jtVJN1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| MXGyOVAyQTdyMR?=
HT-29  NWjvdIN1SXCxcITvd4l{KEG|c3H5 NX[3VYJGOW2P MWO0PIg> MnPHSG1UVw>? MnnQ[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M{PnTFI1QDR{MUW4
Microglia  NW\uXmpDSXCxcITvd4l{KEG|c3H5 NWHDNXFLPW2P M2e0bVI1cA>? M2e2S4Rm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M4LySlI1QDF6NkCx
A2780cp NIPFNmZCeG:ydH;zbZMhSXO|YYm= NHjleIQzNjWvTR?= NXW4OFJQOWh? NH71W3ll\Eh{Tx?= MVflcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo NWPhXmdvOjR6MUe5OFY>
HepG2 NHm4TpJHfW6ldHnvckBCe3OjeR?= NFfkdXU2dU1? M2rwT|Rp NYCwfW4ycW6lcnXhd4V{KEiOIILlcIVie2V? MkXMNlQ4OTN3OEe=
A549 MnzRRZBweHSxc3nzJGF{e2G7 NIPzOJQ2dU1? MlfxOFhp MWjk[YNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdCCmZXH0bEBidmRiZYjwdoV{e2mxbjDs[ZZmdHNib3[gZ4F{eGG|ZT2zMEBD\WOuaX6tNUBidmRiTFOzMWlK Mo\LNlQ4ODZ|MEO=
U2OS MnXkRZBweHSxc3nzJGF{e2G7 M17pfVExdU1? MUmyOIg> NX3Fb5h3cW62ZX7zbYZq\XNidHjlJIdzd3e2aDDpcohq[mm2aX;uJI9nKHSqZTDVNm9UKGOnbHzzJIlv\HWlZXSgZpkhTG:6 MlzqNlQ3OzlyMUO=
Saos-2 NETUOZBCeG:ydH;zbZMhSXO|YYm= NWq1ZmNNOTCvTR?= M{OyZ|I1cA>? NHzGR3pqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? NYLhOmR3OjR4M{mwNVM>
A549 M2fkR2Fxd3C2b4Ppd{BCe3OjeR?= MU[xNI1O M{jKPVQ5cA>? MmLWZYNk\WyncnH0[ZMhfGinIILl[JVkfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDpcoR2[2WmIHL5JHBVYA>? NHjZUVQzPDZ{NkeyNi=>
HCT116  MmDkRZBweHSxc3nzJGF{e2G7 MoTKOY1O NGXG[lIzPGh? M{LVbYVvcGGwY3XzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDhdIlo\W6rbh?= NGTLSlczPDZ{NkWyNi=>
HGC-27 NGHSRVdHfW6ldHnvckBCe3OjeR?= M{DIOlExdU1? MWCxbC=> MmrDbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= NYq2SGNyOjR2MU[zOFk>
U2OS  NYn1b25iTnWwY4Tpc44hSXO|YYm= NXf5b5A1OC53L{HtUS=> MkjHOFhp NXLzVFRlcW6mdXPld{B{[Wyrbn;tfYNqdi2rbnT1Z4VlKGOnbHygeoli[mmuaYT5JIxwe3N? MWiyOFM2QDN2Mh?=
MG-63 M3jCWmZ2dmO2aX;uJGF{e2G7 MUiwMlUwOW2P NF3wUG81QGh? MVTpcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NWi0cnU6OjR|NUizOFI>
MG-63 Mo\SRZBweHSxc3nzJGF{e2G7 Mki4NE42NzGvTR?= NGTzUZA{Omh? M{LJTYVvcGGwY3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= M{DiWFI1OzV6M{Sy
MG-63 NXXDU5V2SXCxcITvd4l{KEG|c3H5 M4PRPVExdU1? MkPINVJp NFXjcJFmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MkfSNlQ{PTh|MEG=
NTUB1 NITUTVBCeG:ydH;zbZMhSXO|YYm= NWLlO401PW2P NUX2VpJ{OS53aB?= MXTwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> Mki5NlQ{PDlzN{[=
T24 M2LObmFxd3C2b4Ppd{BCe3OjeR?= NHPLPZo2dU1? MUKxMlVp MlvadI91\W62aXH0[ZMh[2WuZXPvfIljNWmwZIXj[YQh[XCxcITvd4l{ MV6yOFM1QTF5Nh?=
SGC-7901  MYrBdI9xfG:|aYOgRZN{[Xl? M3\DVlJuVQ>? Ml\pNYg> M3[yXIlv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| MmjpNlQ{OjF|NEC=
SMMC-7721 NUXUTpYySXCxcITvd4l{KEG|c3H5 Mn7zNo1O NFn3XGcycA>? MlvmbY5kemWjc3XzJGNCNTRiaX7keYNm\CCjcH;weI9{cXN? NIPVbXQzPDN{MUO0NC=>
ECSCs  Mk\iRZBweHSxc3nzJGF{e2G7 MlPQNVBuVQ>? NIewNXM1cA>? NUj2VWhF\GWlcnXhd4V{KHKjcHHtfYNqdi22cnXheIVlKGGyb4D0c5Nqew>? MmDINlQ{OTlzMEm=
MCF-7  NVizemg4TnWwY4Tpc44hSXO|YYm= MUOxNI1O NX:4U3Y4OjSq MoDtbY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IHPo[Y1wfGincnHwfUBlenWpcx?= M3PDdFI1OzF3NUe4
UOK257 M4\GTmFxd3C2b4Ppd{BCe3OjeR?= Mkf1OY1O MXOzbC=> NX\WcnpT\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MYeyOFMxPTZyNB?=
ACHN-5968 Mn7DRZBweHSxc3nzJGF{e2G7 NV75Old1PW2P M2TUTlNp M4LLToVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MYqyOFMxPTZyNB?=
Huh7 MWXBdI9xfG:|aYOgRZN{[Xl? MorPNo1O M{Xjd|EzcA>? M4LVeGROW09? MkTqbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= MoTvNlQzQTd|MEC=
Hep3B M1K3WmFxd3C2b4Ppd{BCe3OjeR?= MViycW0> MYCxNog> Mm\WSG1UVw>? MoqybY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= M3ixUVI1Ojl5M{Cw
RKO MkjSSpVv[3Srb36gRZN{[Xl? NVnwTVZoOm2P MWWxbC=> NGexR4hFVVOR NGPrco5mdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> MkDQNlQzQTF5N{e=
HepG2 E47 Ml;nSpVv[3Srb36gRZN{[Xl? NV;SUooxOi53bV2= MYC0PIg> NWe5R|ljcW6lcnXhd4V{KHSqZTD0c5hq[2m2eTDv[kBCSSxiQmPPMEBidmRiQ1PsOC=> NHvnW3MzPDJ5M{ezPC=>
LoVo  MV;BdI9xfG:|aYOgRZN{[Xl? M1y4TlVuVQ>? MVS0PIg> MYjlcohidmOnczDER2EucW6mdXPl[EBieG:ydH;zbZMv MlWyNlQzODF6MUK=
WiDr MXzGeY5kfGmxbjDBd5NigQ>? M1GwT|ExdU1? M33jdVFp MnjDbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v MnLJNlQyQTB2OEm=
H1299  M124R2Z2dmO2aX;uJGF{e2G7 NVzreGlQOTCvTR?= NF3oRWM1cA>? MnrXbY5kemWjc3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NUL6SHJQOjRzN{OyNFg>
H460 MWPGeY5kfGmxbjDBd5NigQ>? NXry[3pUOTCvTR?= NIjQfIM1cA>? NULwSIx5cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? M{j4VVI1OTd|MkC4
A549 M3nGdWZ2dmO2aX;uJGF{e2G7 M2G3TlExdU1? MUW0bC=> MUPpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? NHvGTWozPDF2MkezOS=>
Hep3B NX3Xd|VySXCxcITvd4l{KEG|c3H5 MoH0OY1O NUjGUlNIOjSq MXnheJRmdnWjdHXzJHRPTi4QsTDwdo91\WO2aX;uJIFo[Wmwc4Sgd4VzfW1ic4ThdpZifGmxbj3t[YRq[XSnZDDhdI9xfG:|aYO= NFX4fo0zPDB4Nk[5Ny=>
SMMC-7721 NUj1fI1iSXCxcITvd4l{KEG|c3H5 MX61cW0> MVGyOIg> NHX5XItifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> NY[5W2JQOjRyNk[2PVM>
HO8910 M2LMXGFxd3C2b4Ppd{BCe3OjeR?= MXyxNI1O MYWxNog> NXm4eWti\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? NX\URmtmOjN7OEO2NVA>
MCF7 NILIfHdHfW6ldHnvckBCe3OjeR?= NYixc2dwPW2P NWX3cHo2OjSq NEK3Z5lqdmO{ZXHz[ZMhS3WRIHnu[JVk\WRiY3XscEBl\WG2aB?= MUiyN|k3OjZ{OR?=
HONE-1  MVPGeY5kfGmxbjDBd5NigQ>? MmD6OY1O NYn0T4xIOWh? NV3pNHlLemWycnXzd4V{KD[{LX3l[IlifGWmIGLPV{Bxem:mdXP0bY9v M2f4RVI{QDl{M{W4
HeLa MlXxSpVv[3Srb36gRZN{[Xl? M1nvZVExdU1? M4HSUVJp NXL4S4Z3e3WycILld5NmeyCOQ{OgTWkh\XiycnXzd4l{d25? NIrKdW8zOzh4NEezPC=>
HepG2 MYXGeY5kfGmxbjDBd5NigQ>? NHjTW2UyOG2P MX:yOIg> MYTpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= Mlv2NlM5OTdyNEC=
SH-SY5Y MVXGeY5kfGmxbjDBd5NigQ>? M4LXXlFuVQ>? NEi5NG4zPGh? MlfibY5pcWKrdIOgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTPR3A> M33NfVI{PzR|MUS4
SH-SY5Y NYjlNJZYSXCxcITvd4l{KEG|c3H5 MVy1cW0> M{DOTlFp NIDFN3li[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= M2H4TFI{PjF7M{m1
PC12  NV3rZWNpTnWwY4Tpc44hSXO|YYm= MWSxNI1O M3XS[FI1cA>? NEfPNnR4[XSnch?= NELCdIHDqGmwaHnibZR{KGOqeX3veJJ6eHOrbj3sbYtmKHC{b4TlZZNwdWGuIHHjeIl3cXS7Lh?= MYKyN|YxOzl5OR?=
OV2008 NVrZbI46SXCxcITvd4l{KEG|c3H5 M1P0eFVuVQ>? MXKyOIg> NF\JNHZkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= M{DTVVI{PTl{Mkix
A2780 M4HTcmFxd3C2b4Ppd{BCe3OjeR?= MVK1cW0> MVWyOIg> NWLrRWpn[2:wdnXyeJMhTlS\N{KwJJdqfGhiQ1TEVEBqdnSxIHHuJIFl\Gm2aY\lJIVn\mWldDD0c5diemS|IHvpcIxqdmdib4\hdolidiClYX7j[ZIh[2WubIO= NIX2e3gzOzV7MkK4NS=>
Saos-2  NVSxXWU4SXCxcITvd4l{KEG|c3H5 MnXtNY1O NF;qepo6Pmh? NWraO21NcW6lcnXhd4V{KGOnbHyg[IVifGhiaX7keYNm\CCkeTDQR3g> MVSyN|U3OzF5MR?=
1321N1 Mnq1R5l1d3SxeHnjbZR6KEG|c3H5 MljqOY1O MYiyOIg> Mk\MdJJwfGWldIOgZ4VtdCCjZ3HpcpN1KFCFTj3pcoR2[2WmIITvfIlkcXS7 MV:yN|UzPTJ4NR?=
SH-SY5Y NFPye5dEgXSxdH;4bYNqfHliQYPzZZk> NViwPI9{PW2P NWm1Xpo2OjSq NH;1VIpqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NVS5cI8{OjN3MkWyOlU>
HT-29  NHrZcpFHfW6ldHnvckBCe3OjeR?= NGW0SJMydU1? NFWzPVM1QC97Nni= MmfKbY5pcWKrdIOgRW1RUyCrbnT1Z4V{KGG3dH;wbIFocWNiY3XscEBl\WG2aB?= MlnVNlM2ODh{N{K=
OR6 MkHzSpVv[3Srb36gRZN{[Xl? NXHUOFlLOTCvTR?= MY[3Nog> M3;tVZN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? MYWyN|M6PTh5NR?=
Hela  NH7PUnRHfW6ldHnvckBCe3OjeR?= NUXqfJNbPW2P M2SxTVI1cA>? NVvKWoZMcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? M3[wT|I{Ozl3Nke5
MCF-7  NUnRTGxPTnWwY4Tpc44hSXO|YYm= NXrQO5JVPW2P MofoNlRp M3zo[IlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> M4S4R|I{Ozl3Nke5
HUVECs M1TNOmZ2dmO2aX;uJGF{e2G7 MofON41O MkewNlRp M3XqPYJtd2OtczD0bIUheHKxdHXjeIl3\SCnZn\lZ5Qhd2ZicnXzeoVz[XS{b3ygZpkhcW6qaXLpeIlv\yCjdYTvdIhi\3l? NEL0[oozOzN3OEmyPC=>
T24 MYXGeY5kfGmxbjDBd5NigQ>? NH;mVmsyOG2P MV6xbC=> Mnr4doVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= MXiyN|M2PDB6MB?=
U251MG  M2O4cmZ2dmO2aX;uJGF{e2G7 NEnwSJE{dU1? MmS3NYg> Mkjid5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u MV:yN|M{QDZzOB?=
GTL-16  MoK0RZBweHSxc3nzJGF{e2G7 NIPGSos2dU1? MlK0NlRp MWDy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGG|IHPvcZBiemWmIITvJINmdGy|IITy[YF1\WRid3n0bEBOTVRiaX7obYJqfG:{cx?= M3jkeVI{OzF|NEmw
T-47D MlPpSpVv[3Srb36gRZN{[Xl? M1vmO|ExdU1? NH7yRZMzcA>? NXj3[mk{cW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= NGjOR5UzOzNyMECyOi=>
PaCa44 MofIRZBweHSxc3nzJGF{e2G7 NEH2T4czNjWvTR?= NF7ETHQycA>? NWrSNo9QemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> NFvQT40zOzF{NEGxNi=>
MDA-MB231 M4P5XmZ2dmO2aX;uJGF{e2G7 M1i5cVVuVQ>? MVixbC=> MVjpcoNz\WG|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo NFzaZ3ozOzB6OEi1NC=>
HeLa MVXBdI9xfG:|aYOgRZN{[Xl? NFXufWoyOG2P NWP2eFVWOmh? NGjRUYRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZ48ufHKnYYTt[Y51KHerdHigVGVK MW[yN|AxODF|NR?=
SK-HEP-1 M{TkcWFxd3C2b4Ppd{BCe3OjeR?= M1PIWVExdU1? NGP6b4MycA>? MWPwdo91\WO2czDh[4FqdnO2IHH1eI9xcGGpeTDhcoQhcW6mdXPld{BieG:ydH;zbZMhcW5iYoXmZYxqdi22cnXheIVlKGOnbHzz MmTDNlI5PTh4NEm=
HepG2 M{PX[mFxd3C2b4Ppd{BCe3OjeR?= M1vkSlNuVQ>? NHvFOZk2cA>? M1:1b5Jm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> NYrDeYhSOjJ6M{[1PVU>
MCF-7  MV\GeY5kfGmxbjDBd5NigQ>? M37EdlJuVQ>? M3XGOVI1cA>? NWDNfVVXcW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NX7lSmtiOjR7N{C2O|Y>
MDA-MB-231 M3O4NmZ2dmO2aX;uJGF{e2G7 Mnu1No1O NX\yTG1oOjSq MlvwbY5pcWKrdIOgZZV1d3CqYXf5JIlv\HWlZXSgZpkhXE4EoB?= NYfiXYtIOjR7N{C2O|Y>
MCF-7  NUjDXVAxTnWwY4Tpc44hSXO|YYm= MX6ycW0> NF7kXnI1QGh? NXHBUZl[eHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq NIPXeGwzPDl5ME[3Oi=>
MDA-MB-231 NWTrb2xETnWwY4Tpc44hSXO|YYm= M{LwTVJuVQ>? NWXVfpR[PDiq NXPxTGtqeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq NUnoOFYyOjR7N{C2O|Y>
PANC-1  M{TMZWFxd3C2b4Ppd{BCe3OjeR?= MmjJNY1O Mm\lOFhp M2DTbGROW09? Mk\B[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> Mne1NlQ5PDJzNUi=
MDA-MB 231 MWjBdI9xfG:|aYOgRZN{[Xl? NUPhepFbPW2P M1SzNVAvPWh? MoH5cY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> MV2yOFg{ODd6MR?=
Microglia  NEHGVnlCeG:ydH;zbZMhSXO|YYm= NGLIdZQ2dU1? Mn;YNlRp NEjsPHdl\WO{ZXHz[ZMhcHmyb4jpZU1qdmS3Y3XkJINmdGxiZHXheIg> M2XxNlI1QDF6NkCx
A2780cp MWnBdI9xfG:|aYOgRZN{[Xl? NXPL[oN[Oi53bV2= M2rDelFp MXfk[GgzVw>? M3n0[oVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> Ml3VNlQ5OTd7NE[=
HepG2 MlOwSpVv[3Srb36gRZN{[Xl? NXzkeFhmPW2P M{L4fVRp NEPW[4FqdmO{ZXHz[ZMh[2WubIXsZZIhdGW4ZXzzJI9nKEiOwrC= M4LoWVI1PzF|NUi3
U2OS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DSN|ExdU1? M1O4elI1cA>? M{PHZYlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>? NUHldZZOOjR4M{mwNVM>
HCT116 NEXKe3VCeG:ydH;zbZMhSXO|YYm= MWW1cW0> NEjkSWIzPGh? MVrEUXNQ M3XXbYVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MonyNlQ3OjZ3MkK=
MCF-7  NFfOS2hCeG:ydH;zbZMhSXO|YYm= NFvQOZoxNjGvTR?= MXK2bC=> Mn3v[Y5p[W6lZYOgd4lzfGmwb3ytbY5lfWOnZDDhdI9xfG:|aYO= MXOyNlc2OTl6OR?=
PC-3  MlvzRZBweHSxc3nzJGF{e2G7 NUHtb4VwOm2P M3G3RVJp NHHnUHRqdmO{ZXHz[ZMhV1KLLXnu[JVk\WRiY3XscEBl\WG2aB?= NVjpXmFYOjJ5NEW1PFA>
U251  MmTZRZBweHSxc3nzJGF{e2G7 MUS1cW0> MXqyOIg> M2P2dYlv[3KnYYPld{BUOS2rbnT1Z4VlKGOnbHyg[IVifGh? MlnENlI2Pzl5OEi=
HeLa  M2H5U2Fxd3C2b4Ppd{BCe3OjeR?= M3;zblVuVQ>? M2rBSlI1cA>? NXjDdVNycW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBk\WyuIHTlZZRp NF\jWWgzOjV2NUGyPC=>
A549 NELMUnlHfW6ldHnvckBCe3OjeR?= M4rzZ|AvOW2P MUmyOIg> NX7iOlVoe3WycILld5NmeyCVVUGxNlc1NWmwZIXj[YQh[2WubDDk[YF1cA>? MorONlI1PjZ7NkC=
pDCs M1\sWmZ2dmO2aX;uJGF{e2G7 M2X6ZlExdU1? NFzIbYQxNjWq NWK2cW1TyqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> M2[ydFIzOzl4NUm5
BGC-823 M4fINmZ2dmO2aX;uJGF{e2G7 NG\nVnQ2dU1? M3PnNVJp M1nqVolvcGmkaYTzJJRp\SC{YYTlJI9nKGG3dH;wbIFocWNiY3XscJM> NVnydY9oOjJ|MkKxOVI>
U937 Mnv3SpVv[3Srb36gRZN{[Xl? NXG2VJFGOm2P MmW0NVJp NHK4cppl\WO{ZXHz[ZMhfGinIHH1eI9xcGGpeTDyZZRqd8Li Mk\oNlIyPTVzNUC=
Marc-145 M165O2Z2dmO2aX;uJGF{e2G7 NFH1cVU2dU1? NX\RZmtNOTJxMkSvN|Zp Mn3QdoVlfWOnczD0bIUhWFKUU2[geIl1\XK|IHHu[EB1cGVicILveIVqdiCneIDy[ZN{cW:w MYCyNlEyQTlyMB?=
HBx  M3nqNGFxd3C2b4Ppd{BCe3OjeR?= MnSyNVBuVQ>? NFzPOZE1QGh? MXvEUXNQ M1\2Uolv[3KnYYPld{Bk\WyuIHTlZZRp MoX3NlIxOjByN{i=
MCF-7 MmnVSpVv[3Srb36gRZN{[Xl? NIfVWGMyOG2P M17vVlQ5cA>? NWjzWJlT[myxY3vzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KGKxcoTlfo9ucWJ? MXWyNVk{OTl|Nx?=
RMPI8226  MWHGeY5kfGmxbjDBd5NigQ>? MmL0OY1O M3yzdFFp MoHVd5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? M{TFblIyQTF3NkKw
PC12/TetOn NWnyXXBWTnWwY4Tpc44hSXO|YYm= NIXJWmIxNjFxMX3N MW[xPIg> MljlcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? NH;jVY4zOTlyNk[1PS=>
HeLa  MYfDfZRwfG:6aXPpeJkhSXO|YYm= Ml7oNo1O MVuyOIg> M2fOfolvcGmkaYTld{B1cGViY4n0c5RwgGmlaYT5JI9nKHOrbHnibY5qdiC2bzDI[WxiKGOnbHzzMi=> NEKyNlczOTh5NUO4OS=>
Jurkat MoPVSpVv[3Srb36gRZN{[Xl? M4HhOVExdU1? Mk\pNYg> NHjpdJdl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MkTPNlE5PjRyM{e=
K562 NIn0NXdHfW6ldHnvckBCe3OjeR?= NW\zdVZoOTCvTR?= M{ToXFFp NET6eW5l\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVEN|LVnJJIFv\CC2aHWg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz MVyyNVg3PDB|Nx?=
Nara-H MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[1cW0> NH;uW2E1QGh? NFLRZXZmdmijbnPld{B1\W2|aYLvcIlufXOvZXTpZZRm\CC|dYDwdoV{e2mxbjDv[kBP[XKjLVigZ4VtdCCycn;sbYZmemG2aX;u NWfjU5p5OjF6MEWwN|M>
HUVECs NV6xcGdxTnWwY4Tpc44hSXO|YYm= MYKxNI1O NXnvcFBvOC53aB?= M2nPZoRm[3KnYYPld{B1cGViQVfFMWJUSWmwZIXj[YQh[XW2b4DoZYd6KGyndnW= NYfpR3k3OjF2Nki1PVI>
HepG2 M3nwR2Fxd3C2b4Ppd{BCe3OjeR?= NWPlWVN2Om2P MWmxbC=> MmK2[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MmfINlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
α-SMA / TGF-β / LC-3BI / LC-3B II / Beclin-1 / NF-κB p65; 

PubMed: 29296191     


Western blotting analysed expression of α-SMA, TGF-β, LC-3B, Beclin-1, NF-κB and NF-κBp65 in hepatic stellate cells.

caspase-3 / caspase-9 / PARP; 

PubMed: 25891159     


EC9706 cell lysates were prepared and subjected to immunoblotting with antibodies against caspase-3, caspase-9 and PARP. The expression ratios in each experiment were determined densitometrically. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; PI, propidum iodide; PARP, poly(ADP ribose) polymerase.

VEGF; 

PubMed: 25891159     


Effects of autophagy inhibition on the protein expression levels of VEGF. Western blot analysis demonstrated that VEGF protein expression levels were decreased when the EC9706 human esophageal squamous cell carcinoma cells were treated with 3-MA. The results are the averages of triplicate samples. Error bars represent the standard error.*P<0.05 vs. IR alone. 3-MA, 3-methyladenine; IR, ionizing radiation; VEGF, vascular endothelial growth factor.

APP / BACE1 / ADAM17 / Presenilin 1 / Presenilin 2 / Nicastrin / APH-1 / Pen-2 / LC3-1 / LC3-2; 

PubMed: 26316755     


Presenilin 1, Nicastrin, and Pen-2 were increased with the 3-MA treatment (*P<0.001) while the other component of the γ-secretase complex (APH-1 and Presenilin 2) has no difference. 3-MA, 3-methyladenine; Con, control; APP, amyloid protein precursor.

29296191 25891159 26316755
Immunofluorescence
LC3 / Hif-α / COX2; 

PubMed: 29039446     


Chemical interventions of autophagy and ischemic-hypoxic injury, assessed using immunochemical double labeling. Compared with the control group, expression levels of HIF-α and COX2 were altered by chemical intervention. (A) Chemical intervention altered the expression of HIF-α and autophagosmes. Following autophagy antagonist (3-MA) intervention, expression of HIF-α was enhanced, compared with that in the OGD group, and was decreased by the autophagy agonist, rapamycin. In the MHY treatment group, expression of HIF-α was similar to that in the 3-MA group. (B) Chemical intervention showed changes in the expression of COX2 and autophagosomes. Changes in the expression of COX2 were similar to changes in HIF-α. Scale bar, 30 µm. OGD, oxygen-glucose deprivation; HIF-α, hypoxia-inducible factor-α; COX2, cyclooxygenase 2; 3-MA, 3-methyladenine; RP, rapamycin; MHY, MHY1485.

29039446
Growth inhibition assay
Cell viability; 

PubMed: 26934124     


KYSE 180 cells were co-treated with EDHB (40 μg/ml) and various concentrations of 3-MA for 24 h (left) or 48 h (right), and cell viability was determined by WST-8 assays.

26934124
In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
- Collapse

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
- Collapse
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
- Collapse
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL warmed (67.04 mM)
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389
Smiles C[N]1C=NC(=C2N=CN=C12)N

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I'm also wondering whether it can be dissolved in water,or maybe something like culture medium,normal saline solution to form 10mM solution

  • Answer:

    As the reference (http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal. pone.0035665), 3-MA, which was found to inhibit autophagy at concentrations ranging from 1 to 10 mM was directly dissolved into the culture medium at the indicated concentrations. And we tested the solubility of S2767, and found the solubility of 3-MA in DMEM is 31 mg/mL at about 40°C.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID